Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | HSPA9 | P38646 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567313 | 0.82 | RXRA (0.50) | RARBRARGRARARXRA | |
| SCHEMBL7503006 | 0.79 | RXRA (0.47) | RARBRARGRARARXRA | |
| SCHEMBL7870688 | 0.76 | RARB (0.41) | RARBRARGRARARXRAHDAC8 | |
| SCHEMBL7571992 | 0.76 | RARB (0.41) | RARBRARGRARARXRAHDAC8 | |
| SCHEMBL8328191 | 0.72 | RARB (0.41) | RARBRARGRARAHSPA9AR | |
| SCHEMBL8332981 | 0.72 | RARB (0.41) | RARBRARGRARAHSPA9AR | |
| SCHEMBL8672117 | 0.68 | RARB (0.43) | RARBRARGRARAHSPA9RXRA | |
| SCHEMBL9058675 | 0.67 | RARB (0.49) | RARBRARGRARAHSPA9RXRA | |
| SCHEMBL8365634 | 0.66 | RXRA (0.42) | RARBRARGRARARXRA | |
| SCHEMBL8362259 | 0.66 | RXRA (0.42) | RARBRARGRARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0848696-B1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6313163-B1 | ADMINISTERING 2,4-PENTADIENOIC ACID DERIVATIVE FOR THERAPY OF DISEASE OR CONDITION RESPONSIVE TO THERAPY BY RETINOIDS | ALLERGEN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6114533-A | A COMPOUNDS HAVING A 2,4-PENTADIENOIC ACID OR 2,4-PENTADIENOIC ACID ESTER FUNCTION WHICH IS SUBSTITUTED IN THE 5-POSITION WITH TETRAHYDROQUINOLINYL GROUP | ALLERGAN SALES, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6034242-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1999008992-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5663367-A | REGULATOR OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | RXRA, RXRB, CBR1 | RARB 13/4885RARG 30/4885RARA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.